{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T15:18:20Z","timestamp":1772637500721,"version":"3.50.1"},"reference-count":56,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Fundaci\u00f3 de Recerca de l\u2019Institut de Microcirurgia Ocular","award":["Fi-201401"],"award-info":[{"award-number":["Fi-201401"]}]},{"name":"IMO Grupo Miranza","award":["."],"award-info":[{"award-number":["."]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Gene editing, particularly CRISPR\/Cas technology, represents a promising approach for the treatment of rare genetic diseases, including inherited retinal dystrophies, for which effective therapies are largely unavailable. Despite extensive research investigating gene editing across a wide range of cell types, transient delivery of CRISPR\/Cas components and efficient homology-directed repair (HDR) in differentiated cells remain challenging. In this study, we employed hiPSCs derived from patients with Stargardt disease or Best disease, carrying pathogenic variants in ABCA4 or BEST1, respectively, to explore gene editing in human models. CRISPR\/Cas9 and Cas12 nucleases were delivered into hiPS-derived retinal pigment epithelium (RPE) and retinal organoids using lipoplexes and compared with electroporation. We evaluated transfection efficiency, sgRNA-mediated DNA cleavage, and HDR-based correction. Precise repair of the pathogenic BEST1 variant was successfully achieved in hiPS-derived RPE cells using both nucleases, with Cas12 yielding the highest efficiency, exceeding 10% of HDR correction. Edited RPE cells preserved normal morphology and expressed specific maturity markers. In contrast, retinal organoids exhibited moderate transfection efficiency but showed no detectable CRISPR\/Cas-induced DNA cleavage, highlighting the need for further optimization of gene editing in more complex cellular tissues. This study demonstrates, for the first time, precise correction of a single-nucleotide mutation in patient-derived RPE using CRISPR\/Cas9 and Cas12 delivered using lipoplexes. These findings underscore the therapeutic potential of CRISPR\/Cas-based strategies for inherited retinal dystrophies and provide a proof of concept for future clinical approximations.<\/jats:p>","DOI":"10.3390\/cells15050457","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T08:51:33Z","timestamp":1772614293000},"page":"457","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Precise CRISPR\/Cas9 and Cas12 Correction Using Lipoplexes in Retinal Models Derived from Patients with Inherited Retinal Dystrophies"],"prefix":"10.3390","volume":"15","author":[{"given":"Laura","family":"Siles","sequence":"first","affiliation":[{"name":"Departament de Gen\u00e8tica, Institut de Microcirurgia Ocular, IMO Grupo Miranza, 08035 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheila","family":"Ruiz-Nogales","sequence":"additional","affiliation":[{"name":"Departament de Gen\u00e8tica, Institut de Microcirurgia Ocular, IMO Grupo Miranza, 08035 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"M\u00e9ndez-Vendrell","sequence":"additional","affiliation":[{"name":"Departament de Gen\u00e8tica, Institut de Microcirurgia Ocular, IMO Grupo Miranza, 08035 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Pomares","sequence":"additional","affiliation":[{"name":"Departament de Gen\u00e8tica, Institut de Microcirurgia Ocular, IMO Grupo Miranza, 08035 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Manley, A., Meshkat, B.I., Jablonski, M.M., and Hollingsworth, T.J. (2023). Cellular and Molecular Mechanisms of Pathogenesis Underlying Inherited Retinal Dystrophies. Biomolecules, 13.","DOI":"10.3390\/biom13020271"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"9358","DOI":"10.1038\/s41598-022-13026-2","article-title":"Clinical exome sequencing for inherited retinal degenerations at a tertiary care center","volume":"12","author":"Ganapathi","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1136\/bjophthalmol-2019-315086","article-title":"Macular dystrophies: Clinical and imaging features, molecular genetics and therapeutic options","volume":"104","author":"Rahman","year":"2020","journal-title":"Br. J. Ophthalmol."},{"key":"ref_4","first-page":"53","article-title":"From Serendipity to Scalability in Rare Disease Patient Collaborations","volume":"122","author":"Grens","year":"2025","journal-title":"Mo. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1136\/bjo-2022-321903","article-title":"Genetic treatment for autosomal dominant inherited retinal dystrophies: Approaches, challenges and targeted genotypes","volume":"107","author":"Georgiadis","year":"2023","journal-title":"Br. J. Ophthalmol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1080\/08164622.2021.1880863","article-title":"Gene therapy for inherited retinal diseases: Progress and possibilities","volume":"104","author":"Hu","year":"2021","journal-title":"Clin. Exp. Optom."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/s41580-019-0131-5","article-title":"The next generation of CRISPR\u2013Cas technologies and applications","volume":"20","author":"Gersbach","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s12033-022-00567-0","article-title":"A Review on the Mechanism and Applications of CRISPR\/Cas9\/Cas12\/Cas13\/Cas14 Proteins Utilized for Genome Engineering","volume":"65","author":"Hillary","year":"2023","journal-title":"Mol. Biotechnol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s42003-025-07557-3","article-title":"Comparison of CRISPR-Cas13b RNA base editing approaches for USH2A-associated inherited retinal degeneration","volume":"8","author":"Fry","year":"2025","journal-title":"Commun. Biol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3715","DOI":"10.1038\/s41598-023-29014-z","article-title":"CRISPR\/Cas9 mediated specific ablation of vegfa in retinal pigment epithelium efficiently regresses choroidal neovascularization","volume":"13","author":"Park","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e2416827121","DOI":"10.1073\/pnas.2416827121","article-title":"In vivo photoreceptor base editing ameliorates rhodopsin-E150K autosomal-recessive retinitis pigmentosa in mice","volume":"121","author":"Du","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/s41591-024-03422-8","article-title":"High-efficiency base editing in the retina in primates and human tissues","volume":"31","author":"Muller","year":"2025","journal-title":"Nat. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1016\/j.ymthe.2021.04.002","article-title":"CRISPR technologies for the treatment of Duchenne muscular dystrophy","volume":"29","author":"Choi","year":"2021","journal-title":"Mol. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.21037\/tcr-23-1146","article-title":"Application and progress of CRISPR\/Cas9 gene editing in B-cell lymphoma: A narrative review","volume":"13","author":"Jin","year":"2024","journal-title":"Transl. Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"102010","DOI":"10.1016\/j.eclinm.2023.102010","article-title":"Safety and efficacy of CRISPR-based non-viral PD1 locus specifically integrated anti-CD19 CAR-T cells in patients with relapsed or refractory Non-Hodgkin\u2019s lymphoma: A first-in-human phase I study","volume":"60","author":"Hu","year":"2023","journal-title":"eClinicalMedicine"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s12033-025-01368-x","article-title":"CRISPR\/Cas9 System as a Promising Therapy in Thalassemia and Sickle Cell Disease: A Systematic Review of Clinical Trials","volume":"68","author":"Ahmed","year":"2025","journal-title":"Mol. Biotechnol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s13023-023-02798-z","article-title":"A multidisciplinary approach to inherited retinal dystrophies from diagnosis to initial care: A narrative review with inputs from clinical practice","volume":"18","author":"Murro","year":"2023","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/ceo.13917","article-title":"Inherited retinal diseases: Therapeutics, clinical trials and end points\u2014A review","volume":"49","author":"Georgiou","year":"2021","journal-title":"Clin. Exp. Ophthalmol."},{"key":"ref_19","first-page":"3785","article-title":"Safety and Efficacy of EDIT-101 for Treatment of CEP290-associated Retinal Degeneration","volume":"64","author":"Pierce","year":"2023","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"102236","DOI":"10.1016\/j.omtn.2024.102236","article-title":"Lipid nanoparticle technology-mediated therapeutic gene manipulation in the eyes","volume":"35","author":"Wang","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa2309149","article-title":"CRISPR-Cas9 In Vivo Gene Editing of KLKB1 for Hereditary Angioedema","volume":"390","author":"Longhurst","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e24606","DOI":"10.1016\/j.heliyon.2024.e24606","article-title":"Lipid nanoparticles: The game-changer in CRISPR-Cas9 genome editing","volume":"10","author":"Mokhtari","year":"2024","journal-title":"Heliyon"},{"key":"ref_24","first-page":"e202304","article-title":"Lessons from the first-in-human in vivo CRISPR\/Cas9 editing of the TTR gene by NTLA-2001 trial in patients with transthyretin amyloidosis with cardiomyopathy","volume":"2023","author":"Kotit","year":"2023","journal-title":"Glob. Cardiol. Sci. Pract."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/j.anai.2024.08.048","article-title":"Results from a Phase 2, Randomized, Placebo-Controlled Trial of Crispr-Based Therapy Ntla-2002 for Hereditary Angioedema","volume":"133","author":"Cohn","year":"2024","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Yin, X., Harmancey, R., McPherson, D.D., Kim, H., and Huang, S.L. (2023). Liposome-Based Carriers for CRISPR Genome Editing. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241612844"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"9375","DOI":"10.18632\/oncotarget.14072","article-title":"Targeted delivery of CRISPR\/Cas9 to prostate cancer by modified gRNA using a flexible aptamer-cationic liposome","volume":"8","author":"Zhen","year":"2017","journal-title":"Oncotarget"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"102349","DOI":"10.1016\/j.omtn.2024.102349","article-title":"Direct delivery of Cas9 or base editor protein and guide RNA complex enables genome editing in the retina","volume":"35","author":"Pulman","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.cell.2021.12.021","article-title":"Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins","volume":"185","author":"Banskota","year":"2022","journal-title":"Cell"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"6468","DOI":"10.1038\/s41467-023-42189-3","article-title":"Lipid nanoparticles with PEG-variant surface modifications mediate genome editing in the mouse retina","volume":"14","author":"Gautam","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"101389","DOI":"10.1016\/j.scr.2019.101389","article-title":"Generation of two iPS cell lines (FRIMOi003-A and FRIMOi004-A) derived from Stargardt patients carrying ABCA4 compound heterozygous mutations","volume":"36","author":"Riera","year":"2019","journal-title":"Stem Cell Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"101570","DOI":"10.1016\/j.scr.2019.101570","article-title":"Generation of Best disease-derived induced pluripotent stem cell line (FRIMOi006-A) carrying a novel dominant mutation in BEST1 gene","volume":"40","author":"Riera","year":"2019","journal-title":"Stem Cell Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1186\/s13287-021-02651-9","article-title":"Multiocular organoids from human induced pluripotent stem cells displayed retinal, corneal, and retinal pigment epithelium lineages","volume":"12","author":"Veiga","year":"2021","journal-title":"Stem Cell Res. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.stemcr.2017.07.022","article-title":"Recapitulation of Human Retinal Development from Human Pluripotent Stem Cells Generates Transplantable Populations of Cone Photoreceptors","volume":"9","author":"Kruczek","year":"2017","journal-title":"Stem Cell Rep."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"10646","DOI":"10.1038\/s41598-019-47123-6","article-title":"Automation of human pluripotent stem cell differentiation toward retinal pigment epithelial cells for large-scale productions","volume":"9","author":"Regent","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"102482","DOI":"10.1016\/j.omtn.2025.102482","article-title":"Rescue of the disease-associated phenotype in CRISPR-corrected hiPSCs as a therapeutic approach for inherited retinal dystrophies","volume":"36","author":"Siles","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"W242","DOI":"10.1093\/nar\/gky354","article-title":"CRISPOR: Intuitive guide selection for CRISPR\/Cas9 genome editing experiments and screens","volume":"46","author":"Concordet","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Hwang, G.H., Park, J., Lim, K., Kim, S., Yu, J., Yu, E., Kim, S.-T., Eils, R., Kim, J.-S., and Bae, S. (2018). Web-based design and analysis tools for CRISPR base editing. BMC Bioinform., 19.","DOI":"10.1186\/s12859-018-2585-4"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Davis, M.W., and Jorgensen, E.M. (2022). ApE, A Plasmid Editor: A Freely Available DNA Manipulation and Visualization Program. Front. Bioinform., 2.","DOI":"10.3389\/fbinf.2022.818619"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.omtn.2023.02.032","article-title":"Efficient correction of ABCA4 variants by CRISPR-Cas9 in hiPSCs derived from Stargardt disease patients","volume":"32","author":"Siles","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Siles, L., Gaud\u00f3, P., and Pomares, E. (2023). High-Efficiency CRISPR\/Cas9-Mediated Correction of a Homozygous Mutation in Achromatopsia-Patient-Derived iPSCs. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24043655"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH Image to ImageJ: 25 years of image analysis","volume":"9","author":"Schneider","year":"2012","journal-title":"Nat. Methods"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ymthe.2020.09.032","article-title":"Targeted Knockout of the Vegfa Gene in the Retina by Subretinal Injection of RNP Complexes Containing Cas9 Protein and Modified sgRNAs","volume":"29","author":"Holmgaard","year":"2021","journal-title":"Mol. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"101627","DOI":"10.1016\/j.omtm.2025.101627","article-title":"Retinal organoids mirror CRISPR\/Cas9 gene editing efficiency observed in vivo","volume":"33","author":"Pulman","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1186\/s13287-021-02565-6","article-title":"Homology-directed gene-editing approaches for hematopoietic stem and progenitor cell gene therapy","volume":"12","author":"Azhagiri","year":"2021","journal-title":"Stem Cell Res. Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.stem.2015.01.003","article-title":"Small molecules enhance crispr genome editing in pluripotent stem cells","volume":"16","author":"Yu","year":"2015","journal-title":"Cell Stem Cell"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"113854","DOI":"10.1016\/j.jconrel.2025.113854","article-title":"Lipopeptide-mediated delivery of CRISPR\/Cas9 ribonucleoprotein complexes for gene editing and correction","volume":"383","author":"Nguyen","year":"2025","journal-title":"J. Control. Release"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1016\/j.ymthe.2025.01.042","article-title":"Systematic empirical evaluation of individual base editing targets: Validating therapeutic targets in USH2A and comparison of methods","volume":"33","author":"Tachida","year":"2025","journal-title":"Mol. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Li, F., Wing, K., Wang, J.H., Luu, C.D., Bender, J.A., Chen, J., Wang, Q., Lu, Q., Tran, M.T.N., and Young, K.M. (2020). Comparison of CRISPR\/Cas Endonucleases for in vivo Retinal Gene Editing. Front. Cell. Neurosci., 14.","DOI":"10.3389\/fncel.2020.570917"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/mt.2015.220","article-title":"In vivo CRISPR\/Cas9 gene editing corrects retinal dystrophy in the S334ter-3 rat model of autosomal dominant retinitis pigmentosa","volume":"24","author":"Bakondi","year":"2016","journal-title":"Mol. Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"10059","DOI":"10.1093\/nar\/gkad676","article-title":"Engineered lentivirus-derived nanoparticles (LVNPs) for delivery of CRISPR\/Cas ribonucleoprotein complexes supporting base editing, prime editing and in vivo gene modification","volume":"51","author":"Haldrup","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nbt.3081","article-title":"Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo","volume":"33","author":"Zuris","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.omtm.2018.11.009","article-title":"A Self-Deleting AAV-CRISPR System for In Vivo Genome Editing","volume":"12","author":"Li","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.cell.2020.03.023","article-title":"CRISPR-Based Therapeutic Genome Editing: Strategies and In Vivo Delivery by AAV Vectors","volume":"181","author":"Wang","year":"2020","journal-title":"Cell"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"614","DOI":"10.7150\/thno.47007","article-title":"Strategies in the delivery of Cas9 ribonucleoprotein for CRISPR\/Cas9 genome editing","volume":"11","author":"Zhang","year":"2020","journal-title":"Theranostics"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1080\/10837450.2022.2084554","article-title":"Solid lipid nanoparticles and nanostructured lipid carriers: A review of the methods of manufacture and routes of administration","volume":"27","author":"Akbari","year":"2022","journal-title":"Pharm. Dev. Technol."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/5\/457\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T09:09:05Z","timestamp":1772615345000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/5\/457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":56,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["cells15050457"],"URL":"https:\/\/doi.org\/10.3390\/cells15050457","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]}}}